Lack of oxygen (hypoxia) is a central hallmark of cancer and a pivotal driving force of malignant progression. Transcriptional activators of the hypoxia-inducible factor a (HIFa) family represent the principal molecular mediators of hypoxia under both physiological and pathophysiological conditions. While HIF-2a is expressed in a tissue-and cell-type-restricted manner, stabilization of HIF-1a was reported in tumours of widely different origin, and functional analyses led to the perception of HIF-1a as an oncoprotein. In this review, we aim to acknowledge HIFa's growing complexity by outlining its functional relevance for genomic integrity and tumour heterogeneity, two features of paramount importance for basic and clinical oncology. Pharmaceutical companies around the globe are ambitiously hunting for HIF-1a-inhibiting compounds, some of which are currently being evaluated in phase 1 trials. To avoid the rather disappointing clinical efficacy emblematic of most targeted therapeutics, potential resistance mechanisms of, as well as potential combination partners for, HIF-1a-inhibiting drugs should be evaluated. In this regard, the interrelation of HIF-1a with genomic integrity and tumour heterogeneity offers ample possibilities, potentially resulting in more efficient clinical translation of HIF-1a's pathobiology.
INTRODUCTION
The hypoxia-inducible factor (HIF) transcriptional activators have emerged as the fundamental regulators of oxygen homeostasis. 1, 2 HIFs critically influence development, physiology and numerous diseases by modulating cellular and systemic pathways. 1 HIFs are heterodimeric transcription factors consisting of two basic helixloop-helix proteins of the PAS family (PER, aryl hydrocarbon receptor nuclear translocator and SIM): the oxygen-regulated a-subunit and the constitutively expressed b-subunit (also known as aryl hydrocarbon receptor nuclear translocator). 3, 4 In mammals, three genes have been shown to encode HIFa isoforms by distinct genetic loci. In contrast to HIF-1a, which is widely expressed in tissues, HIF-2a exhibits a more restricted tissue expression. 2, 5 HIF-1a and HIF-2a activate overlapping but distinct sets of target genes, even in a single cell type. 6, 7 Targeted inactivation of HIF-1a and HIF-2a leads to significantly different phenotypes in mouse models. 2 Although the precise function of HIF-3a remains elusive, alternative splicing of HIF-3a generates an inhibitory PAS domain protein that inhibits HIF-1 by forming transcriptionally inactive heterodimers with HIF-1a. 8, 9 Further biochemical aspects of HIFa, for example, the role of prolyl hydroxylases and asparaginyl (factor inhibiting HIF-1) hydroxylases, the von Hippel-Lindau tumour suppressor and the ubiquitin-proteasome pathway, have been covered by numerous excellent reviews and will not be outlined here. This year, the discovery of HIF-1a by Semenza and Wang 10 marks its twentieth anniversary. Thanks to the innovative work by numerous international research groups, our understanding of HIF-1a's role for physiology and disease has risen steadily. Although the picture of HIF-1a was rather lucid in 1992 (one binding partner aryl hydrocarbon receptor nuclear translocator (ARNT), one eponymic stimulus (hypoxia)), we are now confronted with an ever-growing list of cofactors, activators, inhibitors, target genes, signalling pathways and physiological and pathobiological relevancies of HIF-1a. Important aspects of HIF-1a for the pathobiology of cancer, for example, angiogenesis, apoptosis and glucose metabolism, have been extensively covered by previous reviews.
11 -14 In this review, we aim to acknowledge HIF-1a's emerging complexity by discussing pathways and interrelations that, thus far, have lacked major attention but might well be significant to the understanding and, ultimately, clinical translation of HIF-1a biology.
HETEROGENEITY: SECRET FORCE OF TUMOURS AND OBSTACLE FOR RESEARCHERS
The typical manifestation of a solid tumour in clinical imaging procedures is that of a focal lesion, a homogenous-appearing mass. Similarly, tumours in rodent models, especially subcutaneous xenografts, emerge as homogenous nodules with orderly tissue architecture. In fact, however, malignant tumours are anything but well organized and display a huge and functionally relevant amount of heterogeneity at many important levels. 15 The blood vessel network of the tumour represents one paramount driving force of this heterogeneity. The rapid and uncontrolled proliferation of tumour cells confers a categorical dependence on sufficient supply of nutrients and oxygen to the malignant cells. Hence, for a tumour to grow beyond a critical size, it needs to establish its own blood vessel network, a process known as angiogenesis. 16 It is important to note, however, that the newly generated blood vessels are functionally incompetent, as they are highly permeable and lack sufficient control mechanisms of blood flow, for example, because of inadequate pericyte coverage and/or hampered interaction with pericytes. 17 Therefore, angiogenesis not necessarily improves the supply of oxygen and nutrients to the whole tumour, but rather results in further aggravation of tumour heterogeneity owing to the emergence of differently perfused tumour areas. Hypoxia, besides low nutrient concentration, represents the most important functional consequence of the mismatch between tumour cell proliferation and blood supply. The pioneering work of Vaupel et al. 18 has established hypoxia in the tumour microenvironment as a driving force of malignant progression, therapy resistance and, ultimately, limited patient prognosis. Hypoxia typically develops in tumour areas that are located further away from the nearest blood vessel than the oxygen diffusion distance (150-200 mm). This results in a heterogeneous and highly variable distribution of oxygen throughout solid tumours. The functional relevance of hypoxia for malignant progression was elegantly demonstrated on a molecular level by Amato Giaccia's group, providing experimental evidence for a pivotal role of hypoxia in the emergence of tumour cell subpopulations with diminished apoptotic potential due to inactivating p53 mutations. 19 At present, we know that the initial concept of hypoxia as the main and most important driving force of HIF-1a stabilization no longer holds true. It is now widely accepted that biologically relevant HIF-1a stabilization can also occur independently of oxygen, for example, via pro-inflammatory cytokines (for example, interleukin-1b, tumour necrosis factor-a), reactive oxygen or nitrogen species, viral proteins (for example, Hepatitis B and C virus, Epstein-Barr virus), activated oncogenes, loss of tumour suppressor genes and metabolic intermediates, for example, fumarate and succinate. 12, 20 This is demonstrated by the two basic patterns of HIF-1a immunolocalization that are found in human tumours and animal models: heterogeneous HIF-1a positivity of tumour cells distant from blood vessels and/or adjacent to necrotic areas due to hypoxia-induced HIF-1a stabilization and homogeneous staining of neoplastic cells due to genetically or virally mediated activation. 21 We hypothesize that the different patterns of HIF-1a immunolocalization translate into different functional roles of HIF-1a for tumour progression. Hypoxic induction of HIF-1a stabilization is negatively regulated by a plethora of mechanisms (most importantly to avoid sustained activation of HIF-1a after resolution of hypoxia), whereas nonhypoxic induction of HIF-1a (for example, due to mutations of oncogenes or tumour suppressor genes, chronic viral infection or chronic inflammation) is not, or at least to a significantly lesser extent, subjected to negative feedback regulation and is therefore stable over long periods of time. We suggest taking the mechanism(s) of HIF-1a stabilization into account when analyzing (and interpreting) the functional role of HIF-1a for tumour pathogenesis. This notion is supported by the fact that largely different results have been published regarding the effect of HIF-1a inhibition on the malignant potential of tumour cells, ranging from total cessation of growth and robust growth defects to insignificant or even missing effects on tumour cell proliferation. [22] [23] [24] Provided the mechanism of tumoral HIF-1a induction proves to determine the functional outcome of HIF-1a inhibition on tumour growth, we envision the use of the expression pattern of HIF-1a in tumours as a biomarker to predict the efficacy of HIF-1a inhibitors (see below). Obviously, this is an idealized picture and, given the genomic instability of tumours, it is conceivable that both HIF-1a expression patterns can coexist in the same tumour and that transitional stages between the two patterns can be found. Furthermore, the fact that the two main HIFa subunits (HIF-1a and HIF-2a) can exhibit unique and even opposing effects on tumorigenesis needs to be taken into account here. In some tumour types, only one HIFa subunit is associated with aggressive tumour phenotype and poor patient prognosis, reflecting that the respective subunit has a predominant role in this tumour entity. For example, in gastric cancer, solely the expression of HIF-1a has been correlated with poor prognosis, whereas in neuroblastoma and glioblastoma HIF-2a prevails. [25] [26] [27] [28] [29] A detailed overview of the unique roles performed by HIF-1a and HIF-2a in tumour formation is beyond the scope of this article, and the reader is referred to a comprehensive recent review on this topic. 2 
HETEROGENEITY AND METABOLIC REPROGRAMMING OF CANCER
The heterogeneity of tumours has important functional consequences and represents an enormous challenge for valid modelling and systemic analysis of tumour progression. This is nicely exemplified by the heterogeneity of metabolic reprogramming in cancer and the functional importance of HIF-1a in the regulation thereof. The oxygen levels at which cells stabilize HIF1a may differ quite substantially, because cellular sensing of oxygen availability is coupled to the homoeostasis of several metabolites, most of them involved in mitochondrial metabolism. [30] [31] [32] Thus, the modulation of HIF-1a stability must depend on the metabolic activity of the cell. In case of cancer metabolism, there are two implications: first, the enhanced metabolic rates of tumour cells induce a lack of nutrients in the tissue, and second the high metabolic rates of the cells may alter the threshold of oxygen levels for HIF-1a stabilization. 33, 34 Both phenomena are cooperative and lead to a profound induction of HIF-1a activity in a diverse range of tumours. The increased metabolic rates of tumour cells induce starving areas within the solid tumour, and thus are causing a zonation of nutrient availability. 35 Because of this zonation, the cancer genome is exposed to vastly different microenvironments. 36 The outer layer of the tumour is located immediately adjacent to preexisting blood vessels and consumes nutrients at a maximum level, but already the second layer starves for oxygen and other nutrients ( Figure 1 ). 37 Cells located in the starving area of the tumour adapt to these conditions and express an alternative metabolic and signalling network. 38 This may also implicate that these cells respond differently to antiproliferative therapies. 39 As mentioned above, hypoxic conditions confer a selective pressure for the selection of cells with higher malignant potential, for example, via loss of the tumour suppressor p53. 19 The upregulation of HIF-1a may be of pivotal importance in this context, as HIF-1a is able to functionally suppress p53 in cell lines and tissues from different origins. 40, 41 These notions may shed new light on cell culture experiments performed under standard conditions. The artificially high levels of oxygen, nutrients (especially glucose and glutamine) and growth factors in 'normal' growth medium strongly influence cellular behaviour. Furthermore, these conditions do not mirror the conditions tumour cells face in their respective microenvironment. For instance, the glucose concentration of DMEM high glucose medium is equivalent to 450 mg/dl blood glucose, and that of RPMI is equivalent to 200 mg/dl. The normal range of blood glucose lies between 70 and 110 mg/dl, illustrating that two of the most widely used cell culture media do not adequately mirror the glucose situation of the tumour microenvironment. The same can be stated for glutamine, other amino acids, growth factors and hormones. We have conducted a series of experiments to learn more about the influence of nutrient availability on cellular metabolism and function in vitro. HEK293 cells were cultivated at different oxygen and glucose levels, and metabolic activity of glycolysis and the tricarboxylic acid cycle were measured. We observed that HEK293 cells display high rates of glucose uptake and lactate production, hence showing a clear Warburg effect. 42 We found that 95% of the consumed glucose was converted into lactate and finally secreted into the medium (Zasada et al., unpublished observation). Interestingly, the rate of glycolysis was only to a minor extent influenced by oxygen levels, whereas cell growth declined strongly already at 4% oxygen compared with ambient air. We interpret these data in the way that (1) aerobic glycolysis is not regulated by oxygen levels in HEK293 cells and (2) additional oxygen-dependent pathways, for example, glutaminolysis, are able to promote cell proliferation in vitro.
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To date, only a few published studies investigated tumour cell metabolism in vivo. In a seminal study, Fan et al. 44 have analysed human small cell lung cancer samples with stable isotope-resolved metabolomics. Interestingly, their results point towards an upregulation of glycolysis and mitochondrial metabolism in these tumours. Similar observations had already been made by Otto Warburg in the last century during his analyses of the metabolic activity of solid tumours ex vivo. 42 These experiments pointed towards the existence of areas with very low oxygen tension in solid tumours and raised the important question: which processes represent the driving forces of oxygen depletion in tumours? Obviously, cancer cells possess a high affinity for oxygen and harbour variants of enzymes that display low k m values for oxygen. This is mirrored by the observation that cancer cells are able to maintain an oxidative metabolism even under hypoxic conditions. 45 Furthermore, it was shown recently that impairment of mitochondrial metabolism in C-MYC-driven tumours leads to cell death in vitro and in vivo. 46 Taken together, it will be of paramount importance to identify those processes that allow cancer cells to generate hypoxic zones and to better understand which therapeutic consequences arise from the heterogeneous microenvironment present in solid tumours.
THE FUNCTIONAL INTERPLAY OF HIF-1 AND GENOMIC INTEGRITY
Genomic instability and DNA damage are hallmarks of cancer. 16, 47 A detailed description of the various forms of DNA damage and the respective repair mechanisms is out of the scope of this article, and the reader is referred to excellent reviews on this topic. [47] [48] [49] [50] The acquirement of genomic instability in benign and tumour cells is a complex process involving a multitude of mechanisms, for example, oxidative stress, ionizing radiation, UV light exposure, chemotherapeutic drugs, cigarette smoke and food-borne toxins such as nitrates. 47 The functional importance of hypoxia in the context of genomic integrity is rather complex. Although hypoxia in the tumour microenvironment is an accepted driving force of genomic instability, it has to be stressed that hypoxia per se does not inflict any significant DNA damage, neither in benign nor in malignant cells. 51, 52 Indeed, hypoxia interferes rather significantly with the cellular response to DNA damage, and the past decade has substantially broadened our knowledge of the underlying molecular mechanisms. In this context, it is important to note that physical hypoxia is not a single entity, but can be distinguished into different degrees and temporospatial distribution patterns of oxygen. The observation that oxygen levels in tumours vary quite substantially was made by three independent groups 35 years ago. [53] [54] [55] It was subsequently noted that varying oxygen levels can have profound and clinically relevant effects on the malignant phenotype, for example, via inducing resistance to radiotherapy. 56 Interestingly, intermittent hypoxia (IH) in vivo results in HIF-1a activation that is even stronger than the effect of chronic hypoxia. 57 It is noteworthy that the effect of IH on HIF-2a activity is less clear: While IH results in robust stabilization of HIF1a, HIF-2a activity is reduced by IH in the same cell type. 58, 59 Dewhirst et al. 60 have substantially broadened our understanding of the relevance of IH and have introduced the term 'cycling hypoxia' in this context. The reader is referred to one of their comprehensive overviews on this topic. As noted above, the molecular nature of the relationship between hypoxia and genomic instability became clearer in recent years, and the DNA-damage response (DDR) pathway is of particular importance in this setting. 51, 52 The DDR represents an exceedingly complex failsafe mechanism aimed at preventing the transmission of damaged DNA, ultimately sustaining the integrity of the genome. 47 DNA damage is sensed and processed by evolutionary conserved cascades such as ATM/Chk2 (ataxia teleangiectasia mutated gene/checkpoint kinase-2), ATR/Chk1 (ATM-and Rad3-related kinase/ checkpoint kinase-1) and DNAPKs (DNA-dependent protein kinases). 61 Functional inactivation of DDR and checkpoint genes commonly occurs during cancer progression, consolidating genomic instability and driving malignant progression. 62 HIF-1a is remarkably interwoven with molecules centrally involved in DDR and checkpoint control, for example, BRCA1 (breast cancer susceptibility gene 1), ATM, PARP-1 (poly(ADP-ribose) polymerase 1) and DNA-PKs (Figure 2 ). BRCA1 is emerging as a 'master regulator' of genome integrity because of its crucial role in cell cycle checkpoint control and DNA doublestrand break (DSB) repair via homologous recombination. 49 HIF-1a is able to inhibit BRCA1 activity indirectly, that is, by functionally counteracting C-MYC under hypoxic and normoxic conditions. 63 On the other hand, BRCA1 was found to enhance hypoxia-induced stabilization of HIF-1 and expression of the HIF-1 target gene VEGF in breast cancer cells. 64 While these results argue for a negative feedback loop between HIF-1a and BRCA1, an immunohistochemical study showed enhanced abundance of HIF-1a-positive tumour cells in hereditary breast cancer samples with BRCA1 mutations compared with sporadic breast cancers. 65 These contradicting results are most likely explained by the different experimental settings: Kang et al. 64 used RNA interference to knock down BRCA1 in human cell lines established from sporadic breast cancers, and it is reasonable to assume that germline mutations of BRCA1 found in hereditary breast cancer will result in different functional outcomes. In addition to the process of homologous recombination, DNA DSBs can be repaired via non-homologous end joining. Nonhomologous end joining is controlled by the DNA-dependent protein kinase (DNA-PK) complex, three members of which (DNAPKcs, Ku80 and Ku70) have been found to be under transcriptional control by HIF-1a. 66 The DNA-damage-sensing kinase ATM belongs to the phosphatidylinositol-3-OH kinase-related family and mediates the primary response to DNA DSBs. 47, 61 It was recently shown that hypoxia results in ATM activation and that ATM-deficient cells are prone to hypoxia-induced cell death. 67 Strikingly, loss of ATM prevented the stabilization of HIF-1a under hypoxic conditions, establishing ATM as a crucial activator of HIF1a under conditions of oxygen deprivation. 67 Vice versa, HIF-1a can modify the ATM pathway as evidenced by reduced ATM phosphorylation after induction of DNA DSBs in HIF-1a-deficient HIF-1a's role in tumorigenesis N Rohwer et al murine fibroblasts. 66 Similar to ATM, the enzyme PARP-1 functions as a sensor and signal transducer of DNA damage. 48 Whereas ATM is primarily engaged in the repair of DNA DSBs, PARP-1 is central to the process of base excision repair, which reverts more subtle DNA changes, for example, single-strand breaks, oxidative lesions and alkylation products. 47, 48 Functional inactivation of PARP-1 in mice or cells results in robustly impaired base excision repair and genomic instability, suggesting that the enzyme has a pivotal role in the DNA-damage response. 48, 68 Pharmacologic inhibition of PARP-1 resulted in significantly reduced activation of HIF-1a in a murine model of chemical skin carcinogenesis. 69 A crucial role of PARP-1 in the control of HIF-1a stabilization was later confirmed via small interfering RNA-mediated inactivation of PARP-1 in human chronic myeloid leukemia cells and in murine embryonic fibroblasts from PARP-1 knockout mice. 70, 71 It was shown that PARP-1-dependent activation of HIF-1a relies on the enzymatic activity of PARP-1 and that PARP-1 directly interacts with the HIF1a protein, ultimately functioning as a transcriptional coactivator under hypoxic conditions. 70 
INTERACTION OF HIF-1 WITH 'INDIRECT' DNA-DAMAGE RESPONSE PATHWAYS
As recently outlined by Lord and Ashworth 47 in an elegant review, various pathways that are not directly linked to the DDR represent important additional barriers against genomic instability and mutation. Among these are integrity of telomeric DNA (tDNA), ribose 5-phosphate synthesis and chromatin remodelling. 47 All of these mechanisms display functional overlap with HIF-1a, making the importance of HIF-1a for genomic integrity even more complex (Figure 2) . tDNA protects the ends of chromosomes from becoming fused together (end À end fusion) by recruiting various other proteins to form the so-called shelterin complex. 72 Normal somatic cells reduce the length of their tDNA with each cell cycle (telomere attrition) until a critical size is reached that prevents the formation of the shelterin complex. In nontransformed cells, this induces p53-dependent senescence, ultimately preventing the proliferation of aged cells possibly harbouring DNA damage. 73 Hence, proper function of tDNA protects against DNA damage at multiple levels. Although regulation of tDNA integrity is complex and subject to various levels of regulation, basal telomerase activity is critically dependent on the expression of the hTERT (telomerase reverse transcriptase) and hTR (telomerase RNA component) genes. 72 In 2004, it was reported by two independent groups that hypoxia, in a HIF-1a-dependent manner, increased the expression and transcriptional activity of hTERT in vitro. 74, 75 These findings were later confirmed and extended to hTR. 76 In addition, HIF-1a was shown to be a critical regulator of hTERT expression, telomerase activity and telomere length under hypoxia in murine embryonic stem cells. 77 Successful DNA damage repair critically depends on constant replenishment of the deoxynucleotide pool that provides the building blocks of DNA (dATP, dCTP, dGTP and dTTP). 47 As ribose 5-phosphate represents the molecular backbone of all four deoxynucleotides, its biosynthesis can be expected to critically determine the efficacy of the DDR. Ribose 5-phosphate is exclusively produced in the pentose phosphate pathway, an alternative pathway for glucose oxidation that-via generation of NADPH-is essential for redox balance and macromolecular synthesis. 78 Although abundant reports have clearly established the crucial role of HIF-1a for the regulation of glycolysis, there is intriguingly scarce, albeit convincing, experimental evidence for a role of HIF-1a in controlling pentose phosphate pathway activity. Studying the effects of amyloid beta and oxidative stress in the pathogenesis of Alzheimer's disease, the group of David Schubert was the first to report a functional role of HIF-1a for enhanced activity of the pentose phosphate pathway. 79 These results were later confirmed for neuroblastoma cells, pointing towards a critical role of HIF-1a-mediated pentose phosphate pathway activation in cellular protection against oxidative stress, ischemia and hypoxia. 80 The huge abundance of DNA in eukaryotic cells calls for a reliable and dynamic system for packaging, storage and also Figure 2 . HIF-1-dependent mechanisms maintain genomic stability. ATM, ataxia teleangiectasia-mutated gene; BER, base excision repair; HAT, histone acetyl transferase; HDAC, histone deacetylase; HR, homologous recombination; NHEJ, non-homologous end joining; SSB, single-strand break.
HIF-1a's role in tumorigenesis N Rohwer et al rapid accession of the genome. Winding of eukaryotic DNA around histone proteins results in the formation of nucleosomes, which represent the basic unit of packaged DNA. 81 The entire DNA-protein complex is called chromatin. Chromatin organization and the DNA-damage response are functionally intertwined on numerous levels, and the reader is referred to an excellent recent overview on this topic. 82 As a transcription factor, HIF-1a needs access to target DNA sequences for full biological effect, and it is therefore not surprising to note an ever-growing list of functional interactions of HIF-1a and factors involved in chromatin organization. 83 An explicit interaction exists between HIF-1a and the process of histone acetylation. The essential HIF-1a cofactors p300 and CBP represent histone acetyl transferases, and full transcriptional activation of HIF-1a target genes has been shown to require other histone acetyl transferases, for example, PCAF and SRC-3. [84] [85] [86] Interestingly, histone deacetylases also functionally interact with HIF-1a and have been shown to be crucial for HIF-1a's transactivating role. 87 The picture is further complicated by the intriguing observation that a class of histone demethylases (the Jumonji C domain containing demethylases) can function as oxygen sensors and therefore have a role in the hypoxic response. 88 In summary, functional interactions have been described for HIF-1a and central control mechanisms of various forms of DNA repair ( Figure 2 ). In line with this notion, enhanced DNA damage, either inflicted or spontaneous, was shown upon functional inhibition of HIF-1a in vitro. 66, 89 Recent years have shown fascinating improvements of cancer therapy, based on in-depth understanding and targeted inhibition of DDR molecules. This is illustrated by the antiproliferative efficacy of PARP inhibitors: Interference with PARP activity results in stalled and collapsed replication forks, potentially creating detrimental DSBs. 90 Hence, tumour cell survival after treatment with PARP inhibitors relies on efficient repair of these DSBs via homologous recombination. In cells with defective homologous recombination, for example, via germline mutations of BRCA1 or BRCA2, DSB repair cannot be achieved and PARP inhibitors cause cell death. 90 Application of PARP inhibitors to patients suffering from BRCA-defective tumours, for example, hereditary breast cancer patients, has shown remarkable antiproliferative efficacy with very low toxicity. Against this background, the diverse molecular connections between HIF-1a and the DDR raise a number of important and hitherto unanswered questions: Do certain DDR defects confer a special dependence on HIF-1a to safeguard genomic integrity? Do HIF-1a inhibitors kill tumour cells with DDR defects with higher efficacy? If so, to how many DDR defects does this apply and which are most vulnerable to HIF-1a inhibition? Can HIF-1a functionally counteract pharmacological inhibitors of the DDR (for example, PARP-, CHK1-, DNA-PK-and telomerase inhibitors, all in clinical development), thereby reducing their efficacy? Does the combination of DDR-and HIF-1a inhibitors enhance antiproliferative efficacy (with tolerable therapy-associated toxicity)? We believe that addressing these questions holds the potential to significantly improve the treatment outcome of a huge range of malignancies.
HIF-2 AND THE DNA-DAMAGE RESPONSE
In contrast to HIF-1a, the function of HIF-2a in the context of DNA damage is yet easier to comprehend. Analysing 57 cases of sporadic human clear cell renal carcinomas (ccRCC), Celeste Simon and co-workers uncovered a hitherto unknown role of HIF-2a in the regulation of genes important for homologous recombination, for example, BRCA1. 91 In line with this observation, the authors described reduced amounts of DNA damage in HIF-2a-positive ccRCCs. 91 Later, the same group demonstrated a protective function for HIF-2a against radiation-induced DNA damage via suppression of a signalling cascade of reactive oxygen species, ATM/Chk2 (ataxia teleangiectasia mutated/checkpoint kinase-2) and p53 in two ccRCC cell lines. 92 These findings were subsequently extended by Roberts et al., 93 who demonstrated a functional importance of HIF-2a in the resistance of ccRCC cells against chemotherapy, again via suppression of p53. Finally, xenografts of the human ccRCC cell line 786-0 transfected with a HIF-2a expression vector showed enhanced protein abundance of Ogg1 (8-oxoguanine glycosylase-1), a DNA glycosylase important for the execution of base excision repair in response to oxidative DNA damage. 94 Taken together, these results argue for a functional role of HIF-2a in the regulation of ccRCC therapy resistance. 92, 95 It has to be noted, however, that these results were obtained exclusively on ccRCC tissues and cells, where HIF-2a is an established oncoprotein. 95 Whether HIF-2a is of functional importance for DNA-damage response and therapy resistance in other tumour types remains to be elucidated.
HIF-1 AS A THERAPY TARGET: NECESSARY BUT NOT SUFFICIENT?
HIF-1a target genes are critically involved in the regulation of cancer hallmarks such as angiogenesis, epithelial-mesenchymal transition, resistance to apoptosis and anoikis, therapy failure, metabolic reprogramming and metastasis. 13, 14, 21, [96] [97] [98] Furthermore, functional inactivation of HIF-1a results in significant inhibition of tumour growth and malignant progression in numerous murine model systems. 1, 13 A plethora of published papers point towards HIF-1a activation in primary human cancers of different origin and their metastases. 1, 13 In summary, HIF-1a is widely accepted as an attractive target for cancer therapy, and the hunt for HIF-1a-inhibiting compounds is in full effect. Development of efficient and, at the same time, well-tolerated drugs that interfere with HIF-1a is the ultimate goal, and we would like to suggest a number of critical aspects that should be considered. The approval of targeted therapeutics for cancer therapy was paralleled by enormous expectations and almost unlimited optimism by pharmaceutical companies, researchers and physicians. Unfortunately, the majority of newly approved targeted drugs were not able to accomplish substantial and undisputed improvements in patients with solid cancers. 99 This can partially be explained by the emergence of resistant tumour cell subpopulations during targeted therapy, ultimately resulting in therapy failure and disease progression. 99 In addition, targeted drugs carry the potential of severe side effects for example, pneumonitis (everolimus), diarrhea and fatigue (sorafenib), high blood pressure (bevacizumab), as well as rash and other tenacious skin affections (erlotinib), with significant reduction of the patients quality of life. In our opinion, two paramount tasks need to be addressed in order to substantially improve the targeted therapy approach: identification of patient subgroups that are likely to benefit from therapy with targeted drugs and of mechanisms that govern therapy resistance. 99 Plausibility of the former is exemplified by drugs that target the EGF receptor: The overall response to these drugs was disappointing, and subsequent analyses led to the notion that patients with activating mutations of the oncogene ras are resistant to the drug. 100 Accordingly, the approval of EGFR inhibitors for cancer therapy was limited to tumours with wild-type ras. Will it be possible to translate the lessons learned with respect to EGFR targeting drugs to HIF-1a inhibitors, and how could this be approached? Upon an activating stimulus, the HIF-1a protein gets stabilized, translocates to the nucleus, forms HIF-1 via binding of aryl hydrocarbon receptor nuclear translocator and other cofactors and transactivates target gene expression. 13 Hence, immunohistochemical determination of nuclear HIF-1a localization should be a suitable method to verify HIF-1a activation in situ. In fact, immunohistochemistry is frequently being applied to analyse HIF-1a activity in human cancer samples. Although the significance of immunohisto-HIF-1a's role in tumorigenesis N Rohwer et al chemistry is undisputed, potential confounders should be kept in mind when interpreting the obtained data. First, storage time of sections from paraffin-embedded tissue blocks is a critical factor. 101 Preservation of certain antigens declines substantially already in the first 12 weeks after sectioning; therefore, the chance of falsenegative staining results increases with overall storage time of paraffin sections. 102 A valid immunohistochemical analysis of HIF1a can therefore only be achieved when paraffin sections with a storage time of clearly less than 12 weeks are used. Alternatively, sections could always be cut immediately before immunohistochemistry, as paraffin blocks are not, or only marginally, affected by antigen deterioration. 101 However, the feasibility of this approach in daily clinical routine is highly doubtful. Another potentially confounding factor is medication and dietary habits of the patient under investigation, as a multitude of drugs, herbal components and food ingredients have been shown to interfere with HIF-1a stabilization. 103 For example, metformin, ibuprofen, caffeine, green tea polyphenols, n-3 polyunsaturated fatty acids and resveratrol have been attributed potent HIF-1a-inhibiting function. [104] [105] [106] [107] [108] [109] On the other hand, aspirin, insulin and the antiproliferative substance vincristine are examples of drugs that are able to activate HIF-1a. [110] [111] [112] To add even more complexity, certain drugs can either enhance or reduce HIF-1a activity, probably depending on local drug concentration and cellular context, for example, the cholesterol-lowering statins. 113 Taken together, a swarm of divergent factors are able to modify HIF-1a protein stability in human tissue samples. Against this background, a valid determination of tumoral HIF-1a activity via immunohistochemistry is rather difficult to achieve.
In addition to the identification of therapy-predictive biomarkers, we believe that characterization of molecular events that could result in diminished antiproliferative efficacy of HIF-1a inhibitors is of paramount importance. HIF-1a represents a central pro-tumorigenic factor, and hence HIF-1a inhibition will confer substantial pressure on malignant cells to compensate for the loss of HIF-1a and, ultimately, to survive and proliferate in a HIF-1a-independent manner. This is illustrated by the observation that cells harbouring a stable functional inactivation of HIF-1a, for example, via lentiviral transduction of short hairpin RNA, often do not show any growth defect in vitro when compared with the respective wild-type cells. 23, 114 We believe that stable HIF-1a-deficient tumour cell clones represent precious experimental tools as they potentially mirror molecular events that might also confer resistance of human tumours towards HIF-1 inhibitors. Our own unpublished work applying 'omics' analyses (transcriptomics, proteomics and metabolomics) to such cells showed robust activation of factors centrally involved in the regulation of apoptosis, survival, cell cycle and redox balance upon inactivation of HIF-1a (Rohwer et al., in preparation). Interestingly, combined inactivation of HIF-1a and one of the identified factors resulted in strong induction of apoptosis and senescence, ultimately leading to near-complete cessation of cellular survival (Rohwer et al., unpublished observation). We believe that this experimental approach will lead to the identification of multiple pathways whose inhibition hold the potential to enhance the antiproliferative efficacy of HIF-1 inhibitors. Another challenge in HIFa-targeting therapies involves the distinct effects of HIF-1a and HIF-2a on tumorigenesis. It will be critical to determine whether a potential HIFa inhibitor affects both subunits equally or differently. In some tumour entities or certain tumour circumstances, it could be beneficial to inhibit selectively HIF-1a or HIF-2a. For example, inhibiting HIF-2a might be preferable for treating ccRCC, non-small-cell lung cancer and neuroblastoma, whereas HIF-1a-specific therapies could be especially advantageous for highly glycolytic tumour entities.
CONCLUSION
Since its discovery two decades ago, the biology and pathobiology of HIF-1 became remarkably complex. The list of activators, inducers, inhibitors, cofactors and pathobiological relevancies of HIF-1 already is impressively intricate and yet ever growing. Although analyses of tumour-associated angiogenesis dominated the initial years of HIF-1a research, it soon became evident that HIF-1a is able to regulate tumour progression via a multitude of additional mechanisms. HIF-1 is widely accepted as an attractive target molecule for cancer therapy, and we are eagerly awaiting the first results of clinical trials with HIF-1 inhibitors. We propose to take advantage of the rather disappointing clinical experience with targeted therapeutics by taking the obtained bedside knowledge back to the bench in order to optimize the efficacy of HIF-1-inhibiting drugs. Convincing experimental evidence suggests that deconstruction of pathways mediating resistance towards HIF-1 inhibitors and identification of patient subgroups that benefit from treatment with such agents are among the paramount tasks to be performed.
